Blog

  • Dentistry First Announces Introduction of Periodontal Treatment Service in Mooloolaba

    Dentistry First Announces Introduction of Periodontal Treatment Service in Mooloolaba

    Mooloolaba, QLD – December 10, 2025 – PRESSADVANTAGE –

    Dentistry First has announced the introduction of specialised periodontal treatment services at its Mooloolaba clinic. This development aims to improve access to preventive and therapeutic care for patients experiencing gum-related conditions across the Sunshine Coast and nearby regions. The initiative aligns with the clinic’s ongoing focus on early intervention and long-term oral health management.

    The periodontal service will support individuals affected by gum inflammation, bleeding and advanced gum disease, conditions that can lead to tooth loss if not managed properly. Through advanced diagnostic tools and clinical techniques, the practice will address both early-stage gingivitis and more complex cases of periodontitis. According to Dentistry First, the introduction of this service follows a steady increase in public awareness about the connection between gum health and overall well-being.

    dentists

    The treatment process is structured around evidence-based care. Patients will undergo a detailed assessment, including charting, pocket depth measurement and diagnostic imaging when required. Treatment plans may involve deep cleaning procedures such as scaling and root planing, followed by ongoing maintenance visits. Each stage is guided by a focus on reducing inflammation, improving tissue health and preserving the natural dentition wherever possible.

    Periodontal therapy has become an essential part of modern dental practice as research continues to highlight its link to systemic conditions. Studies have shown associations between periodontal disease and diabetes, cardiovascular illness and other inflammatory disorders. The new service offers patients an opportunity to manage these risks through regular dental care, improved hygiene habits and ongoing clinical support. Dentistry First’s investment in this area reflects a growing recognition that oral health is a significant factor in general well-being.

    Dr Jason Phan, lead clinician and prosthodontist at Dentistry First, emphasised that early detection plays a central role in effective periodontal management. “Many people underestimate the seriousness of gum disease because it often progresses without pain,” said Dr Jason Phan. “By offering dedicated periodontal services, we aim to help patients identify and treat issues early, preserving their teeth and supporting overall health outcomes.”

    The periodontal service also incorporates patient education as part of its structure. Each consultation includes guidance on home care practices, proper brushing techniques and the importance of regular professional cleaning. According to the clinic, this collaborative approach encourages individuals to take an active role in maintaining their oral health, which is vital for achieving lasting results.

    Dentistry First’s new program will be available to both existing and new patients. The clinic’s dental professionals will coordinate treatment plans with referring practitioners and specialists when necessary to ensure continuity of care. The addition of this service expands the clinic’s scope, complementing its restorative, cosmetic, and preventive offerings.

    The launch of periodontal treatment comes as part of Dentistry First’s broader initiative to provide more specialised dental care to the community. The clinic, located at 1/45 First Avenue in Mooloolaba, continues to serve residents from across the Sunshine Coast region, including nearby suburbs such as Caloundra, Buderim, and Kawana. Its team remains committed to maintaining high clinical standards through continuous professional development and the use of modern diagnostic technology.

    Dentistry First advises that individuals who experience symptoms such as persistent gum bleeding, swelling, receding gum, or loose teeth should seek professional dental evaluation. These indicators can suggest the presence of periodontal disease, which can often be stabilised with timely treatment. With the new service now available, patients in the region have access to care designed to prevent progression and reduce long-term dental complications.

    For Dentistry First, this addition represents another step in its commitment to advancing oral health outcomes for the Sunshine Coast community. By focusing on prevention and ongoing maintenance, the clinic aims to help patients achieve and maintain healthier smiles for years to come.

    ###

    For more information about Dentistry First, contact the company here:

    Dentistry First
    Jason Phan
    07 5444 4058
    smile@dentistryfirst.com.au
    1/45 First Ave, Mooloolaba QLD 4557

  • Zimman’s Explores How Antique Upholstery in Massachusetts Balances History and Comfort

    Zimman’s Explores How Antique Upholstery in Massachusetts Balances History and Comfort

    LYNN, MA – December 10, 2025 – PRESSADVANTAGE –

    Antique upholstery in Massachusetts continues to reflect a distinct regional relationship with history, craft, and everyday living. Across the state, restored settees, tufted armchairs, and heirloom dining chairs remain more than decorative objects. They function as lived-in pieces that carry stories across generations, often requiring careful decisions about materials, methods, and long-term value.

    Zimman’s has observed that interest in antique furniture has shifted in recent years from purely aesthetic appreciation to a more practical mindset. Collectors, designers, and homeowners are increasingly looking for ways to preserve original character while making pieces more comfortable for contemporary homes. The result is a growing emphasis on restoration upholstering that respects period details without treating antiques as untouchable museum artifacts.

    Massachusetts has long been a natural home for this approach. The state’s architectural mix of Colonial, Federal, Victorian, and early 20th-century styles encourages interior choices that feel historically grounded. Antique furniture often fits naturally into these spaces, but comfort expectations have changed. Modern families may want deeper seating, supportive cushions, or fabrics that can handle daily use. Balancing these preferences with authenticity requires judgment and restraint rather than dramatic transformation.

    One of the most important considerations in furniture restoration is the invisible structure beneath the fabric. Springs, webbing, horsehair, and internal frames often determine whether a piece will last another decade or another fifty years. Skilled upholsterers frequently focus first on stabilizing these foundational elements before selecting exterior materials. This approach helps maintain structural integrity while supporting thoughtful updates in comfort.

    Fabric selection remains one of the most visible ways history and modern living meet. Custom fabrics can be chosen to align with the original era of a piece, echoing period-appropriate patterns, textures, and color ranges. At the same time, newer textiles may offer improved durability or stain resistance, making antique upholstery more compatible with active households. The most successful outcomes tend to avoid extremes, steering clear of fabrics that feel historically out of place or overly delicate for real-world use.

    Designers throughout Massachusetts have also shown increased interest in mixing eras rather than replicating a single time period. In these settings, an antique chair might be reupholstered in a clean, contemporary textile, while its silhouette and detailing remain unchanged. This approach can preserve the furniture’s identity while helping it work within newer design schemes. When done carefully, this kind of custom upholstery update can add relevance without erasing heritage.

    Value preservation remains central to many restoration decisions. Collectors and families with heirloom pieces often benefit from methods that are reversible or minimally invasive. Overly aggressive stripping, heavy structural alterations, or replacing distinctive original features can reduce historical integrity. A measured strategy that prioritizes preservation techniques tends to protect both monetary and sentimental value.

    Massachusetts clients also appear increasingly aware of the importance of documentation. Keeping records of restoration work, including fabric details, method notes, and before-and-after images, supports provenance and clarity for future owners. This practice reflects a broader cultural shift toward transparency in craft and care, especially for pieces that may eventually be passed through families or sold into the antique market.

    Sustainability has become an additional factor influencing interest in antique upholstery in Massachusetts. Restoring an existing piece can reduce demand for newly manufactured furniture and keep well-made frames in circulation. This is particularly meaningful for older furniture constructed with high-quality hardwoods and joinery techniques that are less common in mass-market production today. Restoration, in this context, becomes both an aesthetic choice and a practical one.

    Seasoned artisans across the state continue to play a key role in guiding these decisions. The craft of upholstery is part technical discipline, part design fluency, and part historical interpretation. Experienced workshops can help evaluate what should be conserved, what can be refreshed, and where modern comfort improvements can be introduced without compromising the essence of the piece.

    Zimman’s sees the future of this craft in Massachusetts as increasingly collaborative and informed. The strongest outcomes often emerge when restoration goals are clear: preserve the story, protect the structure, and ensure the furniture can still be enjoyed as a functional, comfortable design. In a region where history is not only remembered but lived alongside the present, antique upholstery remains a practical art form—one that helps homes honor the past without sacrificing the comfort that modern life demands.

    About Zimman’s:

    Founded over a century ago, Zimman’s is a premier fabric, home décor, and furniture store in Lynn, Massachusetts, just outside Boston. Known for its expansive 40,000-square-foot showroom featuring more than 50,000 different fabrics, Zimman’s offers an unparalleled selection of high-quality fabrics, trims, and custom furniture. Catering to interior designers, decorators, and homeowners alike, Zimman’s prides itself on exceptional customer service, expert design guidance, and a unique blend of classic and contemporary products. With a commitment to quality and craftsmanship, Zimman’s continues to set the benchmark for style and excellence in the Boston area.

    ###

    For more information about Zimman’s Inc., contact the company here:

    Zimman’s Inc.
    Daniel Zimman
    daniel@zimmans.co
    80 Market Street Lynn, MA 01901

  • Precision Engineering: ProMed Optimizes the LSR Injection Molding Process for Medical Devices

    Precision Engineering: ProMed Optimizes the LSR Injection Molding Process for Medical Devices

    PLYMOUTH, MN – December 10, 2025 – PRESSADVANTAGE –

    ProMed, a contract manufacturer specializing in liquid silicone rubber (LSR) and highly regulated combination products, has announced new process refinements in the LSR injection molding process designed to support the growing demand for precise, reliable, and fully validated medical-grade components. The company has expanded its engineering controls, material handling standards, and cleanroom capabilities to help OEMs and emerging medtech developers meet increasingly complex performance requirements across drug-delivery systems, implantable devices, and minimally invasive technologies.

    The updates come at a time when medical device teams continue to face tighter tolerances, more demanding regulatory expectations, and accelerated development cycles. ProMed reports that its refined approach is designed to strengthen production repeatability, reduce variability across high-volume runs, and help customers document compliance from early prototyping through commercial scale.

    The optimized process centers on engineered LSR flow control, temperature stability, and metering accuracy. Production teams have implemented expanded in-house testing and more detailed material characterization to ensure predictable curing behavior and dimensional consistency. This includes measuring viscosity ranges, monitoring batch variations, and validating performance against ISO 10993 and FDA biocompatibility requirements. The company has also tightened tool qualification steps, allowing engineers to verify gate design, venting, and part ejection earlier in development. These updates help reduce downstream redesigns and shorten timelines from preliminary samples to validated molds.

    In parallel, ProMed has expanded its ISO Class 7 and 8 cleanroom operations. The facilities now support larger custom LSR injection presses, enhanced positive-pressure controls, and more stringent protocols for managing airborne particulates during molding and assembly. For drug-device customers, segregated cleanroom areas allow for controlled material flow during highly sensitive processes such as mixing, filling, and final device assembly involving active pharmaceutical ingredients. According to the manufacturing team, these changes were implemented to help device developers meet rising expectations in combination-product compliance and quality documentation.

    Tooling refinements also play a central role in the updated process. ProMed’s in-house tool designers have integrated new simulation software to predict LSR behavior in micro-scale features and complex geometries. The simulations guide mold construction, allowing the team to avoid shear-induced imperfections, minimize flash, and maintain uniform wall thickness in components used for implantable valves, seals, stoppers, and drug-eluting devices. The improved approach also supports shorter lead times by allowing more design decisions to be validated digitally before tool steel is cut.

    The updated production framework emphasizes documentation at each stage. Device manufacturers working with ProMed receive structured support during design transfer, including material certifications, molding process sheets, IQ/OQ/PQ documentation, and traceability records. This documentation is particularly valuable for companies preparing for FDA submissions or EU MDR compliance, where detailed evidence of material handling, sterilization compatibility, and manufacturing repeatability is expected.

    Alongside LSR improvements, the company continues to offer high-consistency rubber (HCR) molding, micromolding, and insert molding capabilities for hybrid components that combine metals, plastics, and silicones. As more medical devices integrate electronics, sensors, and mechanical subassemblies, LSR encapsulation and overmolding have become more common. The refined injection molding process improves adhesion, reduces stress on sensitive components, and helps protect electronics during sterilization and long-term use.

    Industry analysts note a growing emphasis on device miniaturization and active pharmaceutical delivery, creating new challenges in material purity and component uniformity. ProMed’s updated LSR process aims to help engineering teams address these challenges by focusing on consistency from lot to lot. The refinements also support device developers who need to scale from pilot runs to commercial quantities without requalifying materials or altering validated molding conditions.

    In addition to production upgrades, the company has also expanded its prototyping services. Development teams can now request rapid-iteration samples using production-grade LSR materials and tooling inserts, allowing earlier functional testing and design confirmation. This reduces the gap between R&D prototypes and commercial-ready components, giving device manufacturers a clearer understanding of performance, durability, and regulatory compatibility earlier in the design cycle.

    As regulatory standards and device requirements continue to evolve, the updated LSR injection molding process demonstrates ProMed’s effort to remain aligned with the needs of medical device engineers, procurement teams, and regulatory specialists. The company intends to continue refining its silicone molding technologies as new materials, biocompatible additives, and device designs reach the market.

    The enhanced production framework is now active across ProMed’s cleanroom facilities and available to both new and existing customers developing medical-grade silicone components. Engineering teams seeking support with early-stage design, tool development, or high-volume LSR molding can coordinate project reviews through ProMed’s technical staff.

    About ProMed:
    Since 1989, ProMed has been recognized as a leading Contract Manufacturer of complex, intricately designed molded silicone and plastic components and assemblies for highly regulated industries. ProMed’s expertise extends across applications for short-term and long-term implantable devices, single-use devices, drug-releasing combination devices, and specialized materials and processes for defense applications. They collaboratively work with our customers from prototype through production, providing over 30 years of experience related to design for manufacturability, material selection, tool and fixture design, process development, manufacturing, and other value-added services that result in cost-effective solutions with superior quality.

    ###

    For more information about ProMed Molded Products, Inc., contact the company here:

    ProMed Molded Products, Inc.
    Jim Reed
    Jim.Reed@ProMedMoldedProducts.com
    15600 Medina Rd, Plymouth, MN 55447

  • SMX: Industry Validation Becomes Industry Visibility

    SMX: Industry Validation Becomes Industry Visibility

    SMX’s second invitation from NAFRA signals a shift from proof to recognition

    NEW YORK, NY / ACCESS Newswire / December 10, 2025 / When an industry organization invites a company into the room, it’s a moment. When that same organization invites the company back after already seeing the technology up close, it’s a message. That is the position SMX (NASDAQ:SMX) occupies now.

    Earlier this year, NAFRA witnessed SMX’s molecular marking and digital passport system achieve 99%-100% accuracy in sorting flame-retardant plastics, including carbon-black materials that had historically evaded standard detection systems. Those results were achieved at industrial speed and verified in a controlled environment that reflects real production conditions. It was the validation every emerging technology needs.

    This morning’s news is different. It moves SMX into a public forum curated by NAFRA and the American Chemistry Council, where the audience no longer evaluates feasibility. They are evaluating relevance. Industry leaders only elevate a technology in this way when they believe the sector should see it. Visibility becomes part of the adoption process, and NAFRA has signaled that SMX has reached that stage. The discussion is no longer about whether the platform works. It is about what the industry should do with a system that has already proven itself.

    Shift to Validation to Visibility

    This shift from validation to visibility is one of the clearest indicators that a technology has crossed an important threshold. The quiet testing phase is over. The conversation now moves toward broader understanding, potential alignment, and the role SMX can play as the sector begins planning how to modernize traceability for flame-retardant plastics. It is a position earned through data, not speculation.

    The accuracy results speak for themselves, and NAFRA’s decision to put SMX in front of a wider group speaks to what those results meant inside the industry.

    The significance of this moment increases when you consider how material standards evolve. Most breakthroughs do not begin with immediate adoption. They begin with recognition from the organizations that set expectations and influence compliance policy. NAFRA sits in that category.

    When they highlight a solution, it tells recyclers, manufacturers, and policy groups that the technology deserves attention. This is how momentum begins. It does not happen through advertising or external promotion. It happens when leaders inside the sector give a technology the platform to be examined openly.

    SMX Has Earned the Industry’s Focus

    SMX enters this phase with a system that aligns with the direction global circularity models are moving. Identity assigned at the molecular level. Traceability supported by digital passports. Verification that keeps integrity across the entire life of a material.

    These capabilities shift the conversation from waste management to material management, which is exactly where NAFRA’s long-term priorities are heading. The return invitation shows that the organization sees value in elevating a tool that can meet regulatory, operational, and compliance requirements all at once.

    This stage also carries weight because visibility attracts different types of stakeholders. Manufacturers will see a technology capable of solving a pain point that has existed for decades. Recyclers will see a path to recovering value from categories of plastic that currently move straight to disposal. Institutional and philanthropic funds, the kind that support climate and materials infrastructure, will see a system that can deliver measurable outcomes instead of relying on estimates. Once a technology reaches this tier of recognition, the audience changes, and the opportunities inside those rooms expand accordingly.

    Industry visibility does not appear by accident. It emerges when a technology has earned the right to be discussed in serious settings by serious decision makers. SMX reached that point by proving accuracy, scalability, and the ability to operate in real conditions. NAFRA’s second invitation confirms that the industry is no longer watching from the sidelines. It is bringing SMX into the conversations that define what comes next.

    About SMX

    As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

    Forward-Looking Statements

    This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, but are not limited to, statements regarding the Company’s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts, events, or circumstances that SMX expects, believes, or anticipates will or may occur in the future, including statements relating to the Company’s business strategy, financial position, future operations, future revenues, projected costs, prospects, plans, and objectives of management, as well as statements regarding the Company’s liquidity position, capital needs, anticipated financing timelines, expected dilution, future share issuances, the anticipated use of proceeds, expected performance of the amended financing agreement, market conditions, adoption of the Company’s technology, commercial pipeline, regulatory approvals, industry trends, competitive position, and any assumptions underlying the foregoing, are forward-looking statements.

    Forward-looking statements are based on the Company’s current expectations and assumptions regarding future events and are subject to a number of risks, uncertainties, and factors that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks relating to: the Company’s ability to successfully execute its operating plans; the Company’s ability to obtain additional financing on acceptable terms or at all; the Company’s ability to maintain compliance with Nasdaq listing standards; market conditions and volatility in the trading price of the Company’s ordinary shares; dilution that may result from the Company’s existing financing arrangements; the Company’s ability to access capital under the standby equity purchase agreement and related amendments; the timing and occurrence of any closings under such agreements; the Company’s expectations regarding its financial runway and future capital needs; risks associated with the Company’s ability to scale its technology, secure customer adoption, or convert pilot programs into commercial deployments; risks relating to supply chain conditions and global economic trends; the Company’s dependence on key personnel; the Company’s ability to maintain intellectual property protection and defend against infringement claims; changes in applicable laws and regulations; general economic, political, and market conditions; risks relating to digital asset markets and the Company’s potential future acquisition or holding of digital assets; and other factors detailed from time to time in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F and its subsequent reports filed with the SEC.

    Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made and are not guarantees of future performance. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. Actual results may differ materially from those anticipated due to various risks and uncertainties, and all forward-looking statements contained herein are qualified in their entirety by this cautionary statement.

    EMAIL: info@securitymattersltd.com

    SOURCE: SMX (Security Matters) Public Limited

    View the original press release on ACCESS Newswire

  • iTrustCapital Surpasses $16 Billion in Total Crypto Transactions, Closing Out a Standout 2025

    iTrustCapital Surpasses $16 Billion in Total Crypto Transactions, Closing Out a Standout 2025

    IRVINE, CALIFORNIA / ACCESS Newswire / December 10, 2025 / iTrustCapital, a leading platform for alternative assets, today announced it has surpassed $16 billion in total crypto transaction volume. This milestone reflects a 60% increase in client activity over the past year and highlights the company’s continued momentum in the digital asset investing space. Achieved only two months after crossing the $15 billion mark, this accomplishment reflects the growing interest from individuals and businesses in making cryptocurrency a vital part of their investment, corporate, and retirement strategies.

    “Reaching this milestone is a great way to close out a remarkable year for our team,” said Kevin Maloney, Chief Executive Officer of iTrustCapital. “As we head into 2026, we’re focused on expanding what’s possible for our clients and continuing to build secure, dependable access to digital assets. The year is poised to be a pivotal one for both the alternative asset and the traditional finance industries.”

    Over the years, iTrustCapital has been consistently recognized for its platform, client experience, and ongoing commitment to innovation. The company was named the #1 Crypto IRA Platform in America at the 2021 IMA Impact Awards and received Best Crypto IRA Investment Platform USA at the 2022 Fintech Awards from Wealth & Finance International. In 2024, iTrustCapital ranked #162 on the Deloitte Technology Fast 500™, and earned the Crypto Award at the US Fintech Awards.

    The strong performance continued in 2025, with iTrustCapital again recognized by the WebAwards for Best Cryptocurrency Website, receiving another Stevie Award for Achievement in Customer Experience, being named one of the 10 Most Innovative Companies of the Year by Business Honor, and earning the title of Top Crypto IRA Retirement Platform from Financial Services Review. The company also received the Impact Award for Digital Currency Company of the Year, adding to a growing list of industry honors.

    iTrustCapital continues to demonstrate strong trust and satisfaction within its community, earning an “Excellent” 4.9-star rating from more than 12,000 client reviews.

    Heading into 2026, the team is focused on building on their momentum with new features, expanded access, and continued improvements designed to support investors at every step. The company expects to follow non-IRA accounts with a stablecoin option and BTC lending product, both slated for Q1-2026.

    About iTrustCapital

    iTrustCapital is a leading fintech software platform for alternative assets. The company provides 24/7 access to digital assets, cryptocurrencies, and precious metals through self-directed, tax-advantaged IRA* and Non-IRA account options. Leveraging a highly secure closed-loop ecosystem and third-party U.S. banks and custodians, iTrustCapital provides greater asset protection and flexibility for a broad range of retail and institutional clients. The company has earned more than 12,000 excellent reviews from Google and Trustpilot, and has successfully executed more than $16B in crypto transactions to date.

    For more information, visit itrustcapital.com.

    *Some taxes may apply.

    iTrustCapital is not an exchange, funding portal, custodian, trust company, licensed broker, dealer, broker-dealer, investment advisor, investment manager, or adviser in the United States or elsewhere. iTrustCapital is not affiliated with and does not endorse any particular digital asset, precious metal or investment strategy.

    Digital assets are a speculative investment with risk of loss. iTrustCapital does not provide legal, investment or tax advice. We recommend seeking the advice of a qualified legal, investment or tax professional.

    CONTACT:

    Kona Bertolino
    Senior Content Marketing Manager
    info@itrustcapital.com
    (562) 600-8399

    SOURCE: iTrustCapital

    View the original press release on ACCESS Newswire

  • SMX Moves Past Proof and Into the NAFRA Room Where Implementation Begins

    SMX Moves Past Proof and Into the NAFRA Room Where Implementation Begins

    NEW YORK, NY / ACCESS Newswire / December 10, 2025 / Some invitations carry more weight because of what happened before them. SMX’s (NASDAQ:SMX) new role as a featured presenter inside a NAFRA and American Chemistry Council program is one of those moments. It does not introduce the company to the sector. It confirms that the sector has already watched and liked how the technology performs. This is a return to a room that knows exactly what SMX brings to the table.

    Earlier this year, SMX completed proof-of-concept trials for identifying and sorting flame-retardant plastic. These trials were conducted in a controlled, industrial configuration with NAFRA oversight. They were designed to answer the only question that matters at the beginning of any materials innovation. Can it work at speed, at scale, with precision that meets real-world demands.

    Those trials delivered 99% to 100% accuracy at 3 m/s, including on carbon-black plastics that standard optical systems fail to reliably identify. They also validated SMX’s integrated stack using molecular markers, high-speed detection, and a digital passport that maintains identity throughout the life of the plastic. This created a foundation of demonstrated capability. It moved SMX out of the category of possibility to proven performance.

    A Room That Represents the Industry’s Core Decision Makers

    The new invitation places SMX in a small, curated forum with the people who define how flame-retardant materials are used, managed, and recycled in North America. These audiences are not passive observers. They shape standards, advise regulators, lead compliance frameworks, and influence how circularity infrastructure evolves across multiple industry segments.

    This matters because NAFRA is not evaluating options in theory. They already watched the technology work. That makes this next meeting a progression rather than an introduction. When a standards-setting group invites a company back, the discussion shifts from feasibility to the practical questions of how a system could be deployed across the value chain.

    Rooms like this also attract institutional and philanthropic capital groups that view circularity as infrastructure. They focus on systems that change outcomes, not marketing claims. They examine technologies that can support long-horizon improvements in traceability, compliance, and material recovery. SMX now sits in that conversation because the data already demonstrated its capability.

    From Demonstration to the Implementation Conversation

    The real story here is not the presentation slot itself. It is the stage of the relationship. SMX has already proven its ability to identify and sort BFR-containing plastics with an accuracy level the industry has not consistently achieved. That step is complete. The next step is to show what an operational rollout could look like when applied across supply chains that require both safety and compliance.

    This is not a sales pitch. It is a strategic engagement. The people in this room are capable of shaping adoption pathways, evaluating how a technology integrates with existing recycling systems, and identifying opportunities for consistent traceability across plastic categories. They are the ones who recognize when a proof point is ready for the next conversation.

    SMX enters this phase positioned to participate in discussions that influence long-term industry direction. The company is no longer establishing that its system works. It is demonstrating why it matters. The invitation signals that the progress made in earlier trials has brought SMX into the part of the process where leaders consider how to build on validated results.

    A Step Forward That Reflects Real Momentum

    The broader implications extend beyond flame-retardant plastics. Once a sector adopts a system that assigns molecular identities, the benefits naturally translate to adjacent categories. Identity becomes a norm. Auditable data becomes expected. Circularity becomes measurable instead of theoretical. This is why early validation inside a high-scrutiny material class carries so much strategic importance.

    For SMX, this next engagement reinforces that molecular identity is shifting from an innovation to a viable structural tool. The company has built a platform that can document the life of a material, enable high-speed identification, and provide transparency aligned with regulatory trends in both North America and abroad. These are qualities that industry leaders consider essential when planning the future of recycling infrastructure.

    The invitation confirms that SMX has reached a new stage. It is not simply demonstrating technology. It is participating in the dialogue that shapes how technology becomes part of a broader system. This is the progression every materials solution needs to reach, and SMX is now firmly inside that zone.

    About SMX

    As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

    Forward-Looking Statements

    This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, but are not limited to, statements regarding the Company’s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts, events, or circumstances that SMX expects, believes, or anticipates will or may occur in the future, including statements relating to the Company’s business strategy, financial position, future operations, future revenues, projected costs, prospects, plans, and objectives of management, as well as statements regarding the Company’s liquidity position, capital needs, anticipated financing timelines, expected dilution, future share issuances, the anticipated use of proceeds, expected performance of the amended financing agreement, market conditions, adoption of the Company’s technology, commercial pipeline, regulatory approvals, industry trends, competitive position, and any assumptions underlying the foregoing, are forward-looking statements.

    Forward-looking statements are based on the Company’s current expectations and assumptions regarding future events and are subject to a number of risks, uncertainties, and factors that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks relating to: the Company’s ability to successfully execute its operating plans; the Company’s ability to obtain additional financing on acceptable terms or at all; the Company’s ability to maintain compliance with Nasdaq listing standards; market conditions and volatility in the trading price of the Company’s ordinary shares; dilution that may result from the Company’s existing financing arrangements; the Company’s ability to access capital under the standby equity purchase agreement and related amendments; the timing and occurrence of any closings under such agreements; the Company’s expectations regarding its financial runway and future capital needs; risks associated with the Company’s ability to scale its technology, secure customer adoption, or convert pilot programs into commercial deployments; risks relating to supply chain conditions and global economic trends; the Company’s dependence on key personnel; the Company’s ability to maintain intellectual property protection and defend against infringement claims; changes in applicable laws and regulations; general economic, political, and market conditions; risks relating to digital asset markets and the Company’s potential future acquisition or holding of digital assets; and other factors detailed from time to time in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F and its subsequent reports filed with the SEC.

    Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date they are made and are not guarantees of future performance. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law. Actual results may differ materially from those anticipated due to various risks and uncertainties, and all forward-looking statements contained herein are qualified in their entirety by this cautionary statement.

    EMAIL: info@securitymattersltd.com

    SOURCE: SMX (Security Matters) Public Limited

    View the original press release on ACCESS Newswire

  • AgentField Launches as the Open-Source “Kubernetes + Okta” for AI Agents

    AgentField Launches as the Open-Source “Kubernetes + Okta” for AI Agents

    New open-source platform provides scale, cryptographic identity, permissions, and tamper-proof audit trails for autonomous software, replacing “god-mode” API keys.

    TORONTO, ON / ACCESS Newswire / December 10, 2025 / AgentField today announced that it has emerged from stealth to do for AI agents what Kubernetes did for containers: turn them into scalable, governed production infrastructure. The new open-source platform solves the “coordination crisis” of autonomous software by assigning every agent a cryptographic identity, ensuring that when AI makes decisions, like spending money or touching data, it does so with enforceable permissions and mathematical proof of authority.

    While designed for any developer deploying autonomous software, this foundation is particularly critical for high-stakes, high-throughput industries-finance, energy, healthcare, logistics, insurance, and critical infrastructure-where small errors can escalate instantly. Across the board, AI is moving out of the chatbot UI and into core systems: reading ledgers, reconciling transactions, and scheduling freight. However, traditional infrastructure cannot support this shift.

    “Autonomous software turns your infrastructure into a digital workforce,” said Oktay Goktas, CEO of AgentField. “That workforce doesn’t log in once a day. It runs constantly in the background, fans out across hundreds of APIs, and executes critical operations at machine speed. You cannot manage millions of autonomous decisions with human-centric SSO or brittle API keys. The identity and orchestration layer has to be rebuilt for autonomous software.”

    The “Coordination Crisis” of Autonomous Software

    When an agent delegates a task, such as moving funds, updating a patient record, or re-routing a shipment, it triggers a chain of downstream actions where a single request cascades into dozens of autonomous decisions. Traditional authorization systems (OAuth, IAM) fail here because they were built for deterministic human workflows; relying on synchronous checks or broad API keys for software that reasons and acts autonomously causes the entire trust model to collapse.

    AgentField solves this by combining Kubernetes-style orchestration with decentralized identity:

    • Cryptographic Identity (DIDs): Every agent receives a W3C Decentralized Identifier.

    • Verifiable Credentials: Agents issue tamper-proof proofs when delegating tasks. A supply chain agent can cryptographically prove it was authorized by a specific risk policy, and that its authority traces back through a chain of agents to an original human or system decision, without needing a central callback.

    • Tamper-Proof Audits: Security teams get cryptographic receipts for every action, not just text logs.

    “We are watching old assumptions break in real time,” said Santosh Kumar Radha, CTO of AgentField. “When a $250,000 transfer happens at 3:17 a.m., you need to know exactly who authorized it and under what policy. AgentField ensures that even if an agent functions autonomously five hops down a chain, its authority can be mathematically verified.”

    Production Infrastructure for Thinking Software

    AgentField provides the control plane for autonomous agents the way Kubernetes provides one for containers, but for identity-bearing, long-running intelligence. Beyond identity, AgentField provides the operational primitives needed to run stateful agents in production:

    • Long-running execution: Support for agents that work on tasks for minutes or hours.

    • Async orchestration: Built-in retries, webhook-based triggers, and backpressure handling for multi-agent workflows.

    • Policy as Code: Access control and IAM policies are enforced by the control plane instead of prompts or ad-hoc scripts.

    Most teams today silently reinvent this backend plumbing with brittle scripts and ad-hoc glue code. AgentField provides it as a coherent, production-grade control plane where trust travels with the agent across systems and organizations, an essential property of a real agent economy.

    Open-Source Strategy & Availability

    AgentField is launching as an Apache 2.0 open-source project available today on GitHub. The founders view open standards as critical for an “agent economy” where software from different vendors must coordinate trustlessly.

    Backed by Panache Ventures and Brightspark Ventures, AgentField was founded by repeat entrepreneurs and PhD holders who previously built Agnostiq and its open-source platform Covalent, acquired by DataRobot in February 2025.

    For more information, visit agentfield.ai.

    ABOUT AGENTFIELD:

    AgentField provides identity and scale infrastructure for autonomous software. Based in Toronto, the company builds the open-source foundations that give AI agents cryptographic identities, delegatable permissions, and production-grade orchestration. Founded by Oktay Goktas, PhD (CEO), and Santosh Kumar Radha, PhD (CTO), who previously built and sold Agnostiq to DataRobot in 2025. Learn more at agentfield.ai.

    MEDIA CONTACT: Nina Pfister, MAG PR at nina@mooringadvisorygroup.com

    SOURCE: AgentField

    View the original press release on ACCESS Newswire

  • FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

    FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

    • Conditional approval extended through December 2026 for the treatment of CID in dogs

    • CID confirmatory effectiveness trial expected to conclude in February 2026, ahead of FDA’s June deadline – 51 dogs enrolled to date; ~49 more expected

    SAN FRANCISCO, CA / ACCESS Newswire / December 10, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the U.S. Food and Drug Administration (FDA) has granted renewal of the conditional approval for Canalevia-CA1 (crofelemer delayed-release tablets). Canalevia-CA1, the company’s prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs, is available from multiple leading veterinary distributors in the U.S., including Chewy. The renewal of conditional approval is in effect until December 21, 2026.

    “Canalevia-CA1 is an important prescription drug for the veterinary community and the thousands of dogs experiencing CID. We’re very pleased about this conditional approval renewal, which, per FDA regulations, is for the fifth and final allowable year of conditional approval for Canalevia-CA1 for the CID indication in dogs. When an animal drug receives conditional approval, the FDA requires that a confirmatory trial take place within 5 years to provide the substantial evidence of effectiveness required for full approval of the drug for the indication,” said Dr. Michael Guy, D.V.M., M.S., Ph.D., Jaguar’s Vice President of Preclinical and Nonclinical Studies. “As announced, our full effectiveness study of Canalevia-CA1 for the treatment of CID in dogs is underway, and this recent conditional approval renewal was granted because we were able to demonstrate active progress toward generating this required data.”

    “Diarrhea is a highly neglected and unmet medical need in dogs and people undergoing cancer treatment,” said Lisa Conte, Jaguar’s president and CEO. “Jaguar is deeply committed to supporting the quality of life of people and animals undergoing cancer treatment.”

    About Conditional Approval and Full Approval

    Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA’s conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the “substantial evidence” standard of effectiveness for full approval. The conditional approval is valid for one year, with up to four annual renewals, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving “substantial evidence of effectiveness” for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.

    About Canalevia®-CA1

    Canalevia-CA1 contains crofelemer, Jaguar’s novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, that modulates chloride channels in the gastrointestinal tract to reduce diarrhea. Importantly, Canalevia is not an antibiotic drug. The overuse and misuse of antibiotics, both in humans and animals, contribute to the development of bacteria that are resistant to antibiotics. Canalevia-CA1, currently conditionally approved by the FDA under application number 141-552, is a tablet that can be given orally twice a day for up to three days and can be used for home treatment of CID in dogs.

    About Chemotherapy-induced Diarrhea (CID) in Dogs

    According to the American Veterinary Medical Association, approximately 1 in 4 dogs will at some stage in their life develop cancer. Nearly half of dogs over 10 will develop cancer.1 According to the National Cancer Institute at the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs yearly in the US.

    Due to the increasing number of chemotherapeutic agents, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,2 and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the US veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.

    Important Safety Information About Canalevia®-CA1

    For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

    Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

    About the Jaguar Health Family of Companies

    Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

    For more information about:

    Jaguar Health, visit https://jaguar.health

    Napo Pharmaceuticals, visit napopharma.com

    Napo Therapeutics, visit napotherapeutics.com

    Magdalena Biosciences, visit magdalenabiosciences.com

    Canalevia-CA1, visit canalevia.com

    Forward-Looking Statements

    Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that the company’s ongoing trial will provide the substantial evidence of effectiveness required for full approval of the drug for treatment of CID in dogs and will conclude in February 2026 with an approximate total of 100 dogs having participated. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

    1 “Cancer in Pets.” American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets

    2 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398

    Contact:

    hello@jaguar.health
    Jaguar-JAGX

    SOURCE: Jaguar Health, Inc.

    View the original press release on ACCESS Newswire

  • Nasdaq Verafin Joins Global Anti-Scam Alliance

    Nasdaq Verafin Joins Global Anti-Scam Alliance

    THE HAGUE, NL / ACCESS Newswire / December 10, 2025 / The Global Anti-Scam Alliance (GASA) is pleased to announce that Nasdaq Verafin has joined GASA as a Foundation Member, strengthening the global effort to combat scams, financial crime, and digital fraud. As fraud tactics continue to evolve across borders and digital channels, cross-sector collaboration has become essential to protecting consumers and building safer financial ecosystems.

    Nasdaq Verafin’s participation marks a meaningful step forward in the shared mission to advance trust, transparency, and resilience across the globe. In addition to joining the global effort, Nasdaq Verafin will join both the Brazil and Mexico chapters of GASA to partner with stakeholders across the financial ecosystem in Latin America, bolstering regional initiatives to combat financial crime.

    “Criminals are innovating at an unprecedented rate, taking advantage of information siloes and the shortcomings of legacy technology to avoid detection. We are at an inflection point in the fight against financial crime, one that requires the entire ecosystem to come together, leveraging the power of collective intelligence to strengthen our defenses and better protect consumers around the globe. We look forward to partnering closely with the Global Anti-Scam Alliance to share innovative solutions, intelligence, and global expertise to the unique challenges financial institutions in Brazil and Mexico face,” said Mauriceo Castanheiro, Head of International Payments Fraud at Nasdaq Verafin.

    Nasdaq Verafin is a global leader in financial crime management technology solutions, trusted by more than 2,700 financial institutions around the globe. The company’s innovative approach combines consortium data, AI, and machine learning to deter, detect, and prevent criminal activity. Nasdaq Verafin’s consortium approach uncovers hidden risks across the financial system, leveraging data and insights from across 800 million counterparties to improve fraud detection and prevention while reducing false positives.

    “Having Nasdaq Verafin join the Global Anti-Scam Alliance as a Foundation Member is a milestone for our organization and for the global fight against scams. Their deep expertise in leveraging technology to more efficiently and effectively detect criminal activity brings a new level of insight and influence to our mission. With Nasdaq Verafin’s partnership, and their representatives joining the boards of our Brazil and Mexico Chapters, we are strengthening our ability to connect global knowledge with local action. Together, we can help shape stronger policies, accelerate industry collaboration, and build the foundations of a scam free future.” said Jorij Abraham, Managing Director of GASA.

    “The addition of Nasdaq Verafin as a Foundation Member is not only a milestone for the Brazil Chapter, it is a strong endorsement of the relevance of our market and the seriousness of the work we have been building from day one. We are starting our journey already alongside a globally recognized institution known for excellence, innovation, and a deep commitment to integrity. This partnership strengthens our ability to translate global expertise into local impact and accelerates our mission to raise the standard of collaboration in the fight against scams and financial crime in Brazil.” said Renata Salvini, Chapter Director for Brazil.

    “With 76 percent of Mexican adults victimized by scams and 139 billion pesos lost annually, according to the 2025 State of Scams in Mexico Report, 2026 will be devastating. AI democratized productivity but industrialized fraud, this isn’t a prediction, it’s a countdown. Combating this epidemic requires integrated defenses where early detection triggers coordinated action across digital platforms, telecommunications, finance, and authorities. Nasdaq Verafin’s addition to GASA Mexico bridges the gap between technology and coordination. Without systemic collaboration, our economic system remains vulnerable. This strengthens our multistakeholder commitment to essential stability”, added Sissi de la Peña, Chapter Director for Mexico.

    Through this partnership, Nasdaq Verafin executives will join the Chapter Advisory Boards of GASA Mexico and Brazil. As a Foundation Member, Nasdaq Verafin will collaborate with GASA and its members, bringing insights from more than two decades of stopping financial crime to develop innovative new strategies that protect consumers from fraud and scams.

    To learn more about Nasdaq Verafin’s approach to financial crime detection and prevention, visit www.verafin.com.

    About the Global Anti-Scam Alliance (GASA)

    The Global Anti-Scam Alliance is a non profit organization whose mission is to protect consumers worldwide from scams. GASA brings together policymakers, law enforcement agencies, consumer authorities, NGOs, the financial sector, telecom operators, internet platforms, service providers, and cybersecurity organizations to share insights, uncover emerging scams, and promote coordinated action against fraud. Learn more at https://www.gasa.org.

    About Nasdaq Verafin

    Nasdaq Verafin provides Financial Crime Management Technology solutions for Fraud Detection and Management, AML/CFT Compliance and Management, High Risk Customer Management, Sanctions Screening and Management, and Information Sharing. More than 2,700 financial institutions, representing 11 trillion dollars in collective assets, use Nasdaq Verafin to prevent fraud and strengthen AML/CFT efforts. Visit www.verafin.com to learn more.

    Cautionary Note Regarding Forward-Looking Statements:

    Information set forth in this release contains forward-looking statements that involve a number of risks and uncertainties. Nasdaq cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Forward-looking statements can be identified by words such as “will”, “may” and other words and terms of similar meaning. Such forward-looking statements include, but are not limited to, statements related to future actions and expected results. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq’s control. These risks and uncertainties are detailed in Nasdaq’s filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q which are available on Nasdaq’s investor relations website at http://ir.nasdaq.com and the SEC’s website at www.sec.gov. Nasdaq undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

    © 2005 Nasdaq, Inc. The Nasdaq logo and the Nasdaq ‘ribbon’ logo are the registered and unregistered trademarks, or service marks, of Nasdaq, Inc. in the U.S. and other countries. All rights reserved. This communication and the content found by following any link herein are being provided to you by Nasdaq, Inc. and/or certain of its subsidiaries (collectively, “Nasdaq”), for informational purposes only. Nasdaq makes no representation or warranty with respect to this communication or such content and expressly disclaims any implied warranty under law. At the time of publication, the information herein was believed to be accurate, however, such information is subject to change without notice. Nothing herein shall constitute a recommendation, solicitation, invitation, inducement, promotion, or offer for the purchase or sale of any investment product, nor shall this material be construed in any way as investment, legal, or tax advice, or as a recommendation, reference, or endorsement by Nasdaq.

    GASA Media Contact
    Metje van der Meer
    Marketing Director
    metje.vandermeer@gasa.org
    +31 6 48456282

    Nasdaq Contact:
    Nick Eghtessad
    Corporate Communications
    nick.eghtessad@nasdaq.com
    + 1 929 996-8894

    SOURCE: Global Anti-Scam Alliance

    View the original press release on ACCESS Newswire

  • Sant’ Andrea University Hospital to Integrate GE HealthCare and Tribun Health’s Enterprise Imaging and Digital Pathology Solutions to Help Improve Patient Care

    Sant’ Andrea University Hospital to Integrate GE HealthCare and Tribun Health’s Enterprise Imaging and Digital Pathology Solutions to Help Improve Patient Care

    GE HealthCare and Tribun Health collaboration helps foster enterprise imaging and pathology for oncology

    CHICAGO, ILLINOIS / ACCESS Newswire / December 10, 2025 / GE HealthCare (Nasdaq: GEHC) announced today that Sant’ Andrea University Hospital, a center of excellence affiliated with Sapienza University of Rome, has chosen the combined strength of GE HealthCare’s Enterprise Imaging platform and Tribun Health‘s CaloPix® digital pathology solution to unify radiology and pathology into a seamless integrated, artificial intelligence (AI)-ready environment.

    With GE HealthCare’s Datalogue[1], including a vendor neutral archive (VNA), and Tribun Health’s award-winning digital pathology platform CaloPix®, Sant’ Andrea is driving to the forefront of a new era in data-driven cancer care. GE HealthCare’s Datalogue helps unify and intelligently manage patient data, images and enterprise imaging content. The Tribun Health Suite is a leading AI-powered end-to-end computational pathology for diagnostics, prognosis and drug development.

    Sant’ Andrea, a public university hospital known for its leadership in oncology and translational research, manages a high volume of complex pathology and imaging cases. This initiative supports its broader mission of accelerating diagnostics, advancing multidisciplinary collaboration, and improving outcomes for patients facing cancer. Sant’ Andrea Hospital is the first in Lazio to implement full digital pathology, with an investment of nearly €1.5 million, about €800,000 of which came from the National Recovery and Resilience Plan.

    “The oncology care pathway is one of the most complex with multiple steps involving a variety of specialists, complex tools, frequent decisions and large data sets,” said Scott Miller, CEO of Solutions for Enterprise Imaging, GE HealthCare. “Sant’ Andrea’s enterprise imaging implementation will help streamline the oncology care pathway across the enterprise and support clinical teams delivering the best care to their patients.”

    “This marks a significant achievement for both Tribun Health and GE HealthCare, and a promising step forward for the future of diagnostic medicine,” said Jean-François Pomerol, CEO of Tribun Health. “Through this collaboration, we’re demonstrating how global partnerships can drive measurable local impact-enhancing efficiency in pathology labs, improving clinical decision-making, and accelerating the delivery of critical insights to patients undergoing cancer care.”

    The digital pathology solutions will help focus on making pathology diagnostic faster and easier for healthcare providers at the point of care. With GE HealthCare’s Datalogue, pathology diagnostic outputs are integrated into an enterprise imaging platform, and can help create a one stop shop for unified clinical data available to clinicians to form decisions. A unified view of clinical patient data is a key asset in oncology for a multi-disciplinary team to be powered by the patient related information and collaborate to define best treatment for the patient in the oncology care pathway.

    “This implementation allows doctors to make faster, more informed decisions and represents a fundamental step in our hospital’s digital transformation,” said Francesca Milito, General Director of AOU Sant’ Andrea. “By unifying radiology and pathology, we improve access to clinical data and create an integrated environment where doctors can make faster and more informed decisions for every cancer patient.”

    Visit here to learn more about GE HealthCare’s enterprise imaging solutions.

    [1]Datalogue is a solution which consists of multiple products, mainly Enterprise Archive and Centricity Universal Viewer Zero Footprint Client.

    GE HealthCare Media Contact:

    Linh Dinh
    M +408 275 5682
    Linh.Dinh@gehealthcare.com

    About GE HealthCare Technologies Inc.

    GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient’s journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

    GE HealthCare is proud to be among 2025 Fortune World’s Most Admired Companies™.

    Follow us on LinkedIn,  X,  Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

    Contact Information

    Andreia Beyer
    VP, Global Marketing & Managing Director, North America
    abeyer@tribun.health
    +1 (416) 565-0474

    .

    View the original press release on ACCESS Newswire